Biosensors International Group, Ltd
Shawn Ang is a Senior Research and Development Engineer at Biosensors International Group, Ltd, where responsibilities include leading engineering efforts for Drug Coated Balloon Catheters and coordinating Clinical Trial sample builds. Prior experience as an R&D Scientist at DIALYSS PTE LTD involved working on a novel medical system for Hemodialysis, focusing on reducing Dialysate usage. As a Chemist at Linxens, Shawn was part of the Precious Metal Management Team, overseeing the purchasing of precious metals. Previous roles also include a Plating Laboratory Chemist at Amphenol ICC, where new chemical analysis methods were developed, and a Laboratory Assistant Engineer at Siltronic AG, responsible for chemical tests in a clean room environment. Shawn holds a Bachelor of Technology in Chemical Engineering from the National University of Singapore and a Diploma in Chemical Engineering from Temasek Polytechnic.
This person is not in any teams
This person is not in any offices
Biosensors International Group, Ltd
Biosensors International develops, manufactures and markets pioneering interventional cardiology devices. The BioMatrix™ DES family features Biolimus A9™ (BA9™), a highly lipophilic anti-restenotic drug designed for cardiovascular stent technologies patented by Biosensors, combined in a unique abluminal biodegradable polymer coating. BioMatrix Alpha™, the latest addition to the family, is a CoCr stent featuring an innovative hybrid design, thin struts and an advanced delivery system. BioFreedom™ demonstrated superior safety and efficacy vs BMS in High Bleeding Risk patients in the landmark LEADERS FREE trial and features a selectively micro-structured abluminal surface allowing polymer & carrier free delivery of BA9™. Recently Biosensors’ parent company made a significant investment into the rapidly growing field of structural heart disease intervention through the acquisition of the company New Valve Technology (NVT), the developers of the flagship product Allegra™ transfemoral TAVI system. Together, Biosensors and NVT will leverage our their respective innovative expertise in Cardiovascular and Structural Heart technologies. Our aim is to improve patients’ lives through pioneering medical technology that pushes the boundaries of innovation. Through our high quality medical devices we impact the lives we touch and we are committed to continued investment in the development of pioneering medical technology, robust clinical data and engineering new medical devices that will further benefit your patients.